Daiken Medical (7775) · TargetSoftened
Medium-Term Targets of ¥11 Billion in Revenue and Other Metrics for the Fiscal Year Ending March 2027
First written in FY2022. 2 of 3 entries say "Softened", first in 2026-05-15. Latest entry: FY2026.
3entries
5years
1from disclosures
How it moved
Same theme, other companies
Setting and achieving performance targets under the medium-term management planA theme 791 companies write about · 75 as a headwind · 1062 as a tailwind
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 133 companies compared. The sentences above are computed from all 133.Comparing 200 of the theme's 1182 threads.Full recordFilings, disclosures and news, newest first
- FY2026SoftenedAnnual report
「当該経営目標数値の達成に向けた計画骨子として、下記３点の重点施策を実施してまいります。」
2027年3月期の売上高110億円等の具体的な目標値は今回明示されず、「当該経営目標数値」の達成に向けた重点施策の説明にとどまっている。 - 2026-05-15SoftenedEarnings
「We plan net sales of ¥10,500 million, up 2.0% year on year; operating income of ¥840 million, down 34.3%; ordinary income of ¥825 million, down 35.3%; and net income of ¥590 million, down 36.1%.」
For the fiscal year ending March 2027, the earnings forecast is net sales of ¥10,500 million, ordinary income of ¥825 million and net income of ¥590 million, compared with medium-term targets including net sales of ¥11,000 million and ordinary income of ¥1,800 million. - FY2022First statedAnnual report
「当面の中期的な経営目標指標として、2027年３月期に売上高110億円、経常利益18億円、当期純利益12.6億円、１株当たり当期純利益43.8円を目指しております。」
2027年3月期を期限として、売上高110億円、経常利益18億円、当期純利益12.6億円、1株当たり当期純利益43.8円という具体的な中期経営目標を初めて明示している。